tradingkey.logo
tradingkey.logo
Search

Bristol Myers' Cobenfy fails to meet main goal as add-on treatment for schizophrenia

ReutersApr 22, 2025 8:20 PM
facebooktwitterlinkedin
View all comments0

- Bristol Myers Squibb BMY.N said on Tuesday its drug Cobenfy failed to show a statistically significant difference compared to a placebo in a late-stage trial studying it as a add-on treatment for schizophrenia.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI